Research & Development
Cerapedics Completes USD 22m Financing
18 July 2018 - - US-based orthobiologics company Cerapedics has closed a USD 22m financing led by KCK Group, a family investment fund that focuses on innovative medical technologies that meet significant clinical needs, the company said.
Funding will accelerate commercialization and US lumbar trial for the iFACTOR Peptide Enhanced Bone Graft, a unique drug-device technology enhances the body's natural bone healing process through cellular activity that is directional and predictable.
The i(FACTOR Peptide Enhanced Bone Graft is based on proprietary biomimetic small peptide technology that has a novel mechanism of action (attract, attach, and activate) that induces osteoblast cell proliferation and differentiation to accelerate new bone formation in patients with degenerative disc disease.
Cerapedics received Premarket Approval from the US FDA for the use of i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion procedures. The company has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion surgery.
Privately held Cerapedics is focused on developing and commercializing its proprietary synthetic small peptide technology platform.
Login
Username:

Password: